2-fluoro-3-methoxyaniline hydrochloride | 1357176-75-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-fluoro-3-methoxyaniline hydrochloride
• 英文别名: 2-Fluoro-3-methoxyaniline hydrochloride；2-fluoro-3-methoxyaniline;hydrochloride
• CAS: 1357176-75-0
• 化学式: C₇H₈FNO*ClH
• 分子量: 177.606
• InChiKey: MFQMAJVFQXQMBG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.84
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  35.2
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-甲基-2-丙基(2-氟-3-甲氧基苯基)氨基甲酸酯 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 3.0h， 生成 2-fluoro-3-methoxyaniline hydrochloride
  参考文献：
  名称：

  [EN] INDAZOLE- AND PYRROLOPYRIDINE-DERIVATIVE AND PHARMACEUTICAL USE THEREOF
  [FR] DÉRIVÉ D'INDAZOLE ET PYRROLOPYRIDINE ET UTILISATION PHARMACEUTIQUE DE CELUI-CI

  摘要：

  本发明涉及一种新型吲唑基或吡咯吡啶基衍生物，由下面的式（1）表示，该衍生物对5-羟色胺-4受体具有激动作用或部分激动作用，并且包括含有该衍生物的药物组合物。式（1）[其中每个取代基如权利要求1所定义]

  公开号：

  WO2012169649A1

文献信息

• INDAZOLE- AND PYRROLOPYRIDINE-DERIVATIVE AND PHARMACEUTICAL USE THEREOF
  申请人：Mizuno Kazuhiro

  公开号：US20140057895A1

  公开（公告）日：2014-02-27

  The present invention relates to a novel indazole- or pyrrolopyridine-derivative comprising a 5 membered heterocyclic substituent at 1 position thereof which has an agonistic action or a partial agonistic action against serotonin-4 receptor, and a pharmaceutical composition comprising the same.

  本发明涉及一种新型吲唑或吡咯吡啶衍生物，其在1位具有一个5成员杂环取代基，具有对5-羟色胺-4受体的激动作用或部分激动作用，以及包含该衍生物的药物组合物。
• QUINOLINE-3-CARBOXAMIDES AS H-PGDS INHIBITORS
  申请人：Astex Therapeutics Limited

  公开号：EP3390384B1

  公开（公告）日：2021-09-15
• CHEMICAL COMPOUNDS
  申请人：GlaxoSmithKline Intellectual Property Development Limited

  公开号：US20210238162A1

  公开（公告）日：2021-08-05

  The present invention relates to compounds of Formula (XI): wherein R 1a , R 2a , R 3a , R 4a , R 5a , R 6a , and Aa are as defined herein, and pharmaceutically acceptable salts thereof. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) inhibitors and can be useful in the treatment of Duchenne Muscular Dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
• [EN] QUINOLINE-3-CARBOXAMIDES AS H-PGDS INHIBITORS<br/>[FR] QUINOLÉINE-3-CARBOXAMIDES UTILISÉS COMME INHIBITEURS DE H-PGDS
  申请人：ASTEX THERAPEUTICS LTD

  公开号：WO2017103851A1

  公开（公告）日：2017-06-22

  The present invention relates to compounds of Formula (XI) wherein R1a, R2a, R3a, R4a, R5a, R6a, and Aa are as defined herein, and pharmaceutically acceptable salts thereof. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) inhibitors and can be useful in the treatment of Duchenne Muscular Dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
• [EN] INDAZOLE- AND PYRROLOPYRIDINE-DERIVATIVE AND PHARMACEUTICAL USE THEREOF<br/>[FR] DÉRIVÉ D'INDAZOLE ET PYRROLOPYRIDINE ET UTILISATION PHARMACEUTIQUE DE CELUI-CI
  申请人：DAINIPPON SUMITOMO PHARMA CO

  公开号：WO2012169649A1

  公开（公告）日：2012-12-13

  The present invention relates to a novel indazole- or pyrrolopyridine-derivative, represented by the formula (1) below, that has an agonistic action or a partial agonistic action against serotonin-4 receptor, and a pharmaceutical composition comprising the same. Formula (1) [wherein each substituent is as defined in claim 1]

  本发明涉及一种新型吲唑基或吡咯吡啶基衍生物，由下面的式（1）表示，该衍生物对5-羟色胺-4受体具有激动作用或部分激动作用，并且包括含有该衍生物的药物组合物。式（1）[其中每个取代基如权利要求1所定义]